BW-20507 / Argo Biopharma - LARVOL DELTA

Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507 (EASL 2025) - "Three subcutaneous doses of BW-20507 were well tolerated and demonstrated a favourable safety profile in patients with CHB. Significant dose-dependent HBsAg reductions have been observed. BW-20507 also has high potency in decreasing HBV DNA."

Clinical • Late-breaking abstract • Fibrosis • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic Hepatitis B Virus (HBV) Infection (ANZCTR) - P1/2 | N=32 | Active, not recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects (ANZCTR) - P1/2 | N=32 | Completed | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Completed

Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic Hepatitis B Virus (HBV) Infection (ANZCTR) - P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd

New P1/2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects (ANZCTR) - P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd

New P1/2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic Hepatitis B Virus (HBV) Infection (ANZCTR) - P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects (ANZCTR) - P1/2 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation